This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ned Sacktor, MD; Xinhua Liu, PhD; Matei Popescu, MD; Karen Marder, MD, MPH; Yaakov Stern, PhD; Richard Mayeux, MD, MSE

Arch Neurol. 1995;52(7):676-679.

Abstract
Objective
To investigate the ability of elevated serum neopterin levels to predict independently mortality, progression to acquired immunodeficiency syndrome, and development of neurological disease.

Design
Cross-sectional and longitudinal study of gay and/or bisexual men and parenteral drug users.

Setting and Patients
Patients included human immunodeficiency virus (HIV)—negative and —positive gay and/or bisexual men and parenteral drug—using men and women who volunteered for an outpatient study of the natural history of HIV infection.

Results
Serum neopterin levels were significantly elevated in HIV-positive patients (mean, 18.0 nmol/L; SD, 19.2 nmol/L), compared with those in HIV-negative patients (mean, 7.5 nmol/L; SD, 5.5 nmol/L) (P<.001). No differences in the serum neopterin levels could be detected between gay men and parenteral drug users. In HIV-positive patients, women had a higher serum neopterin level than did men (P=.03). The elevated serum neopterin levels were associated with an advanced clinical stage of HIV infection. After adjusting for the CD4 lymphocyte count and other potential confounders, the serum neopterin level was a significant independent predictor of mortality. The elevated serum neopterin levels did not predict progression to acquired immunodeficiency syndrome or development of clinically significant neurological disease.

Conclusion
An elevated serum neopterin level predicts mortality, but it does not predict progression to acquired immunodeficiency syndrome or development of neurological disease among HIV-infected individuals.

Author Affiliations
From the Gertrude H. Sergievsky Center (Drs Sacktor, Popescu, Marder, Stern, and Mayeux), the Human Immunodeficiency Virus Center for Clinical and Behavioral Studies, New York State Psychiatric Institute (Drs Sacktor, Liu, Marder, Stern, and Mayeux), and the Departments of Neurology (Drs Sacktor, Marder, Stern, and Mayeux) and Psychiatry (Drs Stern and Mayeux), Columbia University College of Physicians and Surgeons, New York. Dr Sacktor is presently with the Johns Hopkins Bayview Medical Center, Baltimore, Md.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Highly Active Antiretroviral Therapy (HAART) and Circulating Markers of Immune Activation: Specific Effect of HAART on Neopterin
Amirayan-Chevillard et al.
CVI 2000;7:832-834.
ABSTRACT | FULL TEXT